Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Berzosertib + Carboplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Berzosertib||VX-970|VE-822|M6620||ATR Inhibitor 10||Berzosertib (VX-970) is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents resulting in antitumor activity (PMID: 25269479, PMID: 32109490).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Berzosertib + Carboplatin||Phase I||Actionable||In a Phase I trial, Berzosertib (VX-970) and Paraplatin (carboplatin) combination treatment resulted in a best response of stable disease in 71% (15/21) of evaluable patients with advanced solid tumors, including 10 patients with stable disease for 4 months or more and 6 patients with stable disease for 6 months or more (PMID: 32568634; NCT02157792).||32568634|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03517969||Phase II||Carboplatin + Docetaxel Berzosertib + Carboplatin||ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer||Suspended|